Low Dose Rivaroxaban for Atherosclerotic Cardiovascular Diseases: A Systematic Review and Meta-analysis

Low Dose Rivaroxaban for Atherosclerotic Cardiovascular Diseases: A Systematic Review and Meta-analysis

Background: This study aims to explore the role of low-dose rivaroxaban (≤10 mg daily) for the treatment of atherosclerotic cardiovascular disease (ASCVD).Methods: PubMed, Embase and the Cochrane Library were searched for randomized controlled trials (RCTs) of low-dose rivaroxaban in patients with A...

Full description

Bibliographic Details
Main Authors: Can Chen, Yuanqing Kan, Zhenyu Shi, Daqiao Guo, Weiguo Fu, Yanli Li, Qianzhou Lv, Xiaoyu Li, Yi Si
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-02-01
Series:Frontiers in Pharmacology
Subjects:
rivaroxaban
low dose
atherosclerosis
cardiovascular diseases
systematic review
randomized controlled studies
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2020.608247/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2020.608247/full

Similar Items